Discovery of a Novel CIP2A Variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias
A significant fraction of chronic myeloid leukemia (CML) patients relapse from first-generation (1G) tyrosine kinase inhibitor (TKI) therapy, and this could be prevented by the de novo use of 2G TKIs. However, there are no patient stratification markers to guide clinicians in the selection of frontline TKI therapy for optimal outcomes in CML patients. Here, identical results from two independent CML cohorts indicate that the determination of NOCIVA mRNA levels by clinically approved qPCR platforms from de novo chronic phase CML patients could provide significant support for clinicians in recognizing patients in need of first-line 2G TKI therapy. In acute myeloid leukemia (AML), high NOCIVA/CIP2A ratio at diagnosis could indicate a need for first-line therapy intensification.
Recent Posts
-    Participate to Open Hardware Workshop, sign up now! Access to research hardware remains a global challenge and it impacts also researchers in high-income Read moreNovember 3, 2025
 -    The Academy of Finland granted Johanna Ivaska €2,400,000 in funding for an Academy Professor position The Academy of Finland granted our Group Leader, Professor Johanna Ivaska €2,400,000 in funding for Read moreOctober 30, 2025
 -    Guillaume Jacquemet and Cecilia Sahlgren receive funding for the Research Council of Finland Centre of Excellence in Immune-Endothelial Interactions (IMMENs) Associate Professor Guillaume Jacquemet, our Group Leader, and Professor Cecilia Sahlgren, our affiliated Group Leader, Read moreOctober 30, 2025
 -    Registration to AI2Med imaging event is now open! Registration for AI2Med Turku 2025 is open! The event is organized by the Turku PET Read moreOctober 21, 2025
 -    Jonna Alanko receives the Young Investigator Award from the Scandinavian Society for Immunology Jonna Alanko has received the Young Investigator Award of the Scandinavian Society for Immunology. The Read moreOctober 17, 2025
 -    Professor Riitta Lahesmaa awarded Johnny Ludvigsson Prize for Outstanding Nordic Researcher Professor Riitta Lahesmaa was awarded Johnny Ludvigsson Prize for Outstanding Nordic Researcher. The prize is Read moreOctober 16, 2025